Copolymer with lower limit of critical solution temperature (LCST) shifting reversibly in response to light in specific wavelength region, and method for producing the same
A copolymer with photoresponsive and temperature-responsive groups addresses the toxicity and indiscriminate release of anticancer drugs by selectively targeting and killing cancer cells with light-activated drug delivery.
Patent Information
- Application Number
- JP2023076365
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-02
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing drug carriers for anticancer drugs are highly toxic to normal cells and release drugs indiscriminately due to temperature or pH changes, posing risks to normal cells and lacking spatial and temporal control.
A copolymer with photoresponsive and temperature-responsive groups that selectively targets cancer cells, shifting its lower critical solution temperature (LCST) in response to specific light wavelengths, allowing controlled drug release and uptake.
The copolymer selectively targets and kills cancer cells without harming normal cells, achieving spatial and temporal control through light-activated drug delivery.
Smart Images

Figure 2024160875000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a copolymer whose lower critical solution temperature (LCST) reversibly shifts in response to light in a specific wavelength range, and also to a method for producing such a copolymer. [Background technology]
[0002] In recent years, the number of people suffering from or dying from cancer has been increasing worldwide (see Non-Patent Document 1). Therefore, today, various cancer treatment methods, such as surgical therapy, radiation therapy, and chemotherapy, have been established. Among these, chemotherapy is used by many people suffering from cancer because it is expected that anticancer drugs will be effective on the whole body and multiple anticancer drugs can be used in combination. However, chemotherapy causes anticancer drugs to remain in the whole body by oral administration or injection, and may affect not only cancer cells but also normal cells. As a result, chemotherapy may cause severe side effects, such as hair loss, nausea, and organ damage, in people undergoing cancer treatment.
[0003] Many studies have been conducted to establish methods to reduce the side effects of such anticancer drugs. For example, a representative example is a drug carrier that recognizes the difference in temperature and pH between the surroundings of normal cells and cancer cells and releases drugs only around the cancer cells (see Non-Patent Document 2). [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Ahmedin, J. et al. CA CANCER J CLIN, 2018, 68, 394. [Non-Patent Document 2] Yatvin MB, et al. Science. 1978, 202, 1290. Summary of the Invention [Problem to be solved by the invention]
[0005] However, in the above method, the drug carrier contains an anticancer drug that is highly toxic to normal cells. In addition, if the drug carrier collapses due to changes in temperature or pH, all of the anticancer drug in the drug carrier is released at once. This causes a rapid increase in the concentration of the anticancer drug in the body, which may have a significant effect on normal cells. In addition, since the above method uses temperature and pH changes as external stimuli to collapse the drug carrier, it may be difficult to apply the stimuli only to a specific area.
[0006] The objective of the present invention is to provide a copolymer that satisfies all of the following conditions: it does not require the use of anticancer drugs that are highly toxic to cells; it is selectively taken up by cancer cells; and it has minimal adverse effects on normal cells and can kill cancer cells by applying an external stimulus that is controllable in time and space. [Means for solving the problem]
[0007] The copolymer according to the first aspect of the present invention includes a first monomer-derived component having a photoresponsive group that is reversibly hydrophobized or hydrophilized in response to light in a specific wavelength range, a second monomer-derived component having a functional group that selectively binds to a sugar chain expressed on the surface of a cancer cell, and a third monomer-derived component having a temperature-responsive group that is reversibly hydrophobized or hydrophilized in response to temperature. The copolymer according to the first aspect of the present invention also reversibly shifts its lower critical solution temperature (LCST) in response to light in a specific wavelength range. For convenience of explanation, such a copolymer may be referred to as an "LCST photoshift copolymer" below.
[0008] The copolymer having the above-mentioned configuration contains a first monomer-derived component and a third monomer-derived component, so that when it is irradiated with light in a first specific wavelength range, its LCST shifts to a lower temperature side, and when it is irradiated with light in a second specific wavelength range, its LCST shifts to a higher temperature side. Therefore, for example, if the LCST on the lower temperature side of this copolymer is set to be lower than body temperature and the LCST on the higher temperature side of the copolymer is set to be higher than body temperature, the copolymer can be precipitated or redissolved in the body by selectively irradiating it with light in a specific wavelength range. In addition, the copolymer having the above-mentioned configuration contains a second monomer-derived component, so that it is selectively taken up by cancer cells.
[0009] The copolymer according to a second aspect of the present invention is the copolymer according to the first aspect, which has an LCST in the range of 40° C. or more and 100° C. or less when irradiated with ultraviolet light, and an LCST in the range of 0° C. or more and 37° C. or less when irradiated with visible light.
[0010] As a result of intensive studies by the present inventors, the LCST of the copolymer having the above-mentioned configuration when irradiated with ultraviolet light is in the range of 40°C to 100°C. In addition, the LCST of the copolymer having the above-mentioned configuration when irradiated with visible light is in the range of 0°C to 37°C. In addition, as a result of intensive studies by the present inventors, it was confirmed that when the copolymer having the above-mentioned configuration, which has been irradiated with ultraviolet light in advance to shift the LCST to a higher temperature, is brought into contact with normal cells and cancer cells in an environment of 37°C, which is close to the temperature of the body, the copolymer is selectively taken up by the cancer cells. In addition, it was suggested that when visible light is irradiated to cancer cells that have taken up the copolymer, the LCST of the copolymer shifts to a lower temperature, and the copolymer precipitates in the cancer cells. As a result, it was suggested that the copolymer induces the death of cancer cells by being present as a foreign body in the cancer cells. From the above, it was suggested that the copolymer having the above-mentioned configuration can selectively kill only cancer cells.
[0011] In the copolymer according to the second aspect, the range of the temperature obtained by subtracting the LCST upon irradiation with visible light from the LCST upon irradiation with ultraviolet light (hereinafter, sometimes referred to as the "LCST shift range") is not particularly limited, but is, for example, within the range of 3° C. or more and 100° C. or less. Note that this LCST shift range can be appropriately adjusted by adjusting the monomer ratios of the first monomer, the second monomer, and the third monomer described below.
[0012] A third aspect of the present invention is a cancer therapeutic agent comprising the copolymer according to the first or second aspect as an active ingredient.
[0013] A method for producing a copolymer according to a fourth aspect of the present invention is a method for copolymerizing a first monomer having a photoresponsive group that reversibly becomes hydrophobic or hydrophilic in response to light in a specific wavelength range, a second monomer having a functional group that selectively binds to a sugar chain expressed on the surface of a cancer cell, and a third monomer having a temperature-responsive group that reversibly becomes hydrophobic or hydrophilic in response to temperature.
[0014] In the above-mentioned method for producing a copolymer according to the present invention, the first monomer is preferably spiropyran acrylate (SPAA). In the above-mentioned method, the monomer ratio of the first monomer material used for polymerization is preferably within the range of 5 mol% to 30 mol%.
[0015] In the above-mentioned method for producing the copolymer according to the present invention, the second monomer is preferably 4-acrylamido-3-fluorophenylboronic acid (AFBA). In the above-mentioned method, the monomer ratio of the second monomer material used for polymerization is preferably within the range of 5 mol% to 30 mol%.
[0016] In the above-mentioned method for producing the copolymer according to the present invention, the third monomer is preferably oligo(ethylene glycol) methacrylate (OEGMA). In the above-mentioned production method, the charged monomer ratio of the third monomer material used for polymerization can be appropriately changed depending on the charged monomer ratio of the above-mentioned first monomer material and the charged monomer ratio of the second monomer material, the desired LCST value, etc.
[0017] In addition, the above-mentioned production method is preferably a method of copolymerizing the above-mentioned first monomer, the above-mentioned second monomer and the above-mentioned third monomer so that the LCST of the copolymer obtained by the method is within a range of 40°C or more and 100°C or less when irradiated with ultraviolet light, and the LCST is within a range of 0°C or more and 37°C or less when irradiated with visible light. Effect of the Invention
[0018] According to the present invention, it is possible to selectively take up into cancer cells and kill cancer cells by an external stimulus of light that can be controlled in time and space, without using anticancer drugs that are highly toxic to cells. Here, by irradiating the copolymer taken up into the cancer cells in the body with light in the wavelength range of visible light, it is possible to selectively kill only the cancer cells without adversely affecting normal cells. Moreover, according to the present invention, it is possible to produce such a copolymer. [Brief description of the drawings]
[0019] [Figure 1] FIG. 1 shows the H-NMR spectra of AFBA, SPAA, OEGMA, and P(AFBA-co-SPAA-co-OEGMA). [Diagram 2] FIG. 1 is a diagram showing the temperature dependence of light transmittance of phosphate buffered saline (PBS(-) / culture medium (v / v=1 / 1)) containing P(AFBA-co-SPAA-co-OEGMA) according to Example 1. [Diagram 3]FIG. 1 is a photograph of phosphate buffered saline (PBS(-) / culture medium (v / v=1 / 1)) containing P(AFBA-co-SPAA-co-OEGMA) according to Example 1, irradiated with visible light having a wavelength of more than 400 nm for 10 seconds at 37°C. [Figure 4] FIG. 1 shows the results of evaluating the uptake behavior of P(AFBA-co-SPAA-co-OEGMA) into (a) L929 cells, (b) HepG2 cells, and (c) HeLa cells. [Diagram 5] Figure 1 shows the results of fluorescence microscopy of (a) L929 cells, (b) HepG2 cells, and (c) Hela cells after exposure to P(AFBA-co-SPAA-co-OEGMA) for 4 hours. [Figure 6] FIG. 1 shows the cell viability of (a) HepG2 cells and (b) HeLa cells at each concentration when exposed to or not exposed to visible light. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] (LCST light shifting copolymer) The LCST photoshift copolymer according to the embodiment of the present invention is a copolymer having a property of reversibly shifting the LCST in response to light in two or more different specific wavelength ranges, and examples thereof include copolymers having a photoresponsive group that reversibly becomes hydrophobic or hydrophilic in response to light in two or more different specific wavelength ranges. Examples of such photoresponsive groups include functional groups that reversibly ionize and deionize in response to light in two or more different specific wavelength ranges, or functional groups that undergo cis-trans isomerization, such as a spiropyran group (reversibly zwitterionized / deionized) and an azobenzene group as shown in the following chemical formula:
[0021] [ka]
[0022] [ka] In synthesizing this LCST photoshift copolymer, it is preferable to copolymerize a first monomer-derived component having a photoresponsive group as described above, a second monomer-derived component having a functional group that selectively binds to glycans expressed on the surface of cancer cells, and a third monomer-derived component having a temperature-responsive group that reversibly becomes hydrophobic or hydrophilic in response to temperature.
[0023] (1) First monomer-derived component The first monomer-derived component has a photoresponsive group (photoresponsiveness) that reversibly becomes hydrophobic or hydrophilic in response to light of two or more different specific wavelength ranges. 1 The introduction ratio of the component derived from the first monomer calculated from the results of H-NMR measurement is preferably within the range of 5 mol % to 30 mol %.
[0024] The first monomer-derived component constituting the LCST photoshift copolymer according to the embodiment of the present invention is represented by the following formula (1):
[0025] [ka] It is preferable that the compound has the structure shown in FIG.
[0026] The first monomer-derived component having the structure shown in the above formula (1) can be obtained, for example, by carrying out a polymerization reaction using spiropyran acrylate (SPAA) as a monomer material.
[0027] In addition, examples of monomer materials for the first monomer-derived component include, in addition to the above-mentioned SPAA, spiropyran methacrylate, spiropyran norbornene carboxylate, azobenzene (meth)acrylate, stilbene (meth)acrylate, retinol (meth)acrylate, diarylethene 4-vinyl benzoate ester, and the like.
[0028] (2) Second monomer-derived component The second monomer-derived component has a functional group that selectively binds to glycans expressed on the surface of cancer cells. The functional group here is boronic acid (-B(OH) 2 In the copolymer according to the present invention, it is preferable that the functional group contains the following. 1 The introduction ratio of the component derived from the second monomer calculated from the results of H-NMR measurement is preferably within the range of 5 mol % to 30 mol %.
[0029] The second monomer-derived component constituting the LCST photoshift copolymer according to the embodiment of the present invention is represented by the following formula (2):
[0030] [ka] It is preferable that the compound has the structure shown in FIG.
[0031] The second monomer-derived component having the structure shown in the above formula (2) can be obtained, for example, by carrying out a polymerization reaction using 4-acrylamido-3-fluorophenylboronic acid (AFBA) as a monomer material.
[0032] In addition, examples of monomer materials for the second monomer-derived component include, in addition to the above-mentioned AFBA, phenylboronic acid derivatives, vinyl-modified lectins, and vinyl-modified selectins.
[0033] (2) Third monomer-derived component The third monomer-derived component has a temperature-responsive group that reversibly becomes hydrophobic or hydrophilic in response to temperature. 1 The introduction ratio of the component derived from the third monomer calculated from the results of H-NMR measurement is preferably within the range of 40 mol % to 90 mol %, but is not limited to this range.
[0034] The third monomer-derived component constituting the LCST photoshift copolymer according to the embodiment of the present invention is represented by the following formula (3):
[0035] [ka] It is preferable that the compound has a structure as shown in the following formula (3). In the above formula (3), the numerical value "x" can be a value of 1 or more and 100 or less. The value of x can be appropriately changed depending on the mixing ratio of the above-mentioned first monomer-derived component and the second monomer-derived component, the desired LCST value, and the like. The value of x is preferably 1 or more and 10 or less. By setting the value of x to 10 or less, the mixing ratio of the above-mentioned first monomer-derived component and the second monomer-derived component can be appropriately adjusted. In addition, the LCST can be easily adjusted to around body temperature.
[0036] The value "x" in the above formula (3) may be different for each of the components derived from the third monomer in the copolymer. For example, the third monomer component may have x=3.35. This value is the average of the values of x for each of the components derived from the third monomer in the copolymer.
[0037] The third monomer-derived component having the structure shown in the above formula (3) can be obtained, for example, by carrying out a polymerization reaction using oligo(ethylene glycol) methacrylate (OEGMA) as a monomer material.
[0038] In addition to the above-mentioned OEGMA, examples of monomer materials for the third monomer-derived component include, for example, N-isopropylacrylamide (NIPAAm), methoxypoly(ethylene glycol) methacrylate (PEGMA), methoxypoly(ethylene glycol) acrylate, poly(ethylene glycol) (meth)acrylate, 2-hydroxyethyl (meth)acrylate, methoxyethyl (meth)acrylate, 2-methacryloyloxyphosphorylcholine, methoxyoligo(ethylene glycol) acrylate, methoxyoligo(propylene glycol) (meth)acrylate, alkylacrylamide and its derivatives, vinyl ether and its derivatives, and alkylcellulose derivatives.
[0039] In addition, when synthesizing the LCST photoshift copolymer, other monomers than those mentioned above, for example, monomers for adjusting the LCST, may be copolymerized. When the LCST is set to a high temperature side, a monomer having a hydrophilic group may be copolymerized, and when the LCST is set to a low temperature side, a monomer having a hydrophobic group may be copolymerized.
[0040] The LCST photo-shifting copolymer according to the embodiment of the present invention may have various copolymer structures such as random copolymer, alternating copolymer, periodic copolymer, block copolymer, graft copolymer, etc., but is preferably a random copolymer. P(AFBA-co-SPAA-co-OEGMA) synthesized in the examples described later is a random copolymer.
[0041] The LCST photoshift copolymer according to the embodiment of the present invention is a terpolymer synthesized using three types of monomers, but may be a tetrapolymer synthesized using four types of monomers.
[0042] <Example> The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the examples shown below. EXAMPLES
[0043] 1. Synthesis of P (AFBA-co-SPAA-co-OEGMA) First, 0.203g (0.50mmol) of spiropyran acrylate (SPAA), 1.135g (3.90mmol) of oligo(ethyleneglycol)methacrylate (OEGMA) from which the polymerization inhibitor had been removed using an activated alumina column, 0.148g (0.05mmol) of 4-acrylamide-3-fluorophenylboronic acid (AFBA), and 8g (0.05mmol) of 2,2'-azobis(isobutyronitrile) (AIBN) as a polymerization initiator were collected in an eggplant flask, and 20mL of ethanol was added to dissolve them. Next, the solvent in the eggplant flask was frozen using liquid nitrogen, and the pressure in the eggplant flask was reduced for 10 minutes using a vacuum pump. After the pressure was reduced, the eggplant flask was warmed to about 20°C to thaw the solvent in the eggplant flask. This operation was repeated three times to remove the gas in the eggplant flask. Then, argon gas was filled into the eggplant flask, and the eggplant flask was placed under an argon atmosphere, and the eggplant flask was heated to 65°C to start the polymerization reaction. After 8 hours had passed since the start of the polymerization reaction, the solution obtained by the polymerization was placed in a cellulose dialysis membrane (molecular weight cutoff: 3500) and dialyzed using methanol for three days. At this time, 350 mL of methanol was used at one time. In addition, in this dialysis, the dialysis external solution was exchanged nine times. Then, the solution after dialysis was distilled under reduced pressure in an environment of 30°C and 110 mmHg using a rotary evaporator to obtain a deep red viscous solid. The viscous solid obtained by the reduced pressure distillation was vacuum dried using a desiccator for three days to completely remove the methanol, thereby obtaining a deep red solid. The yield of the solid was 74.3%. The chemical reaction at this time is as shown in the following chemical reaction formula.
[0044] [ka] Then, the mixture was analyzed by a nuclear magnetic resonance spectrometer (NMR: JNM-ECZL-400 (400 MHz), solvent: CDCl 3 The solid was identified using the NMR spectroscopy. 1 The H-NMR spectrum is shown in Figure 1. It was confirmed that the peaks at around 5.4 to 6.4 ppm originating from the vinyl groups of AFBA, SPAA, and OEGMA disappeared after polymerization. In addition, a peak originating from AFBA was confirmed at around 8.0 ppm, a peak originating from SPAA at around 8.5 ppm, and a peak originating from OEGMA at around 2.0 ppm. Furthermore, the peaks were broadened, so the deep red solid obtained above was identified as P(AFBA-co-SPAA-co-OEGMA).
[0045] In Table 1 below, "In feed (mol%)" indicates the monomer ratio of each monomer material used in the polymerization, and "In polymer (mol%)" indicates the 1 The ratio of monomer-derived components introduced is calculated from the results of H-NMR. In addition, "Yield (%)" in Table 1 indicates the yield of P(AFBA-co-SPAA-co-OEGMA) obtained by copolymerization.
[0046] [Table 1] 2. Evaluation of P (AFBA-co-SPAA-co-OEGMA)
[0047] (1) Confirmation of LCST shift phenomenon by light irradiation The light transmittance at a wavelength of 650 nm was measured at each temperature for phosphate buffered saline (PBS(-) / culture medium (v / v=1 / 1)) containing P(AFBA-co-SPAA-co-OEGMA) (1.0 mg / ml) (hereinafter referred to as "P(AFBA-co-SPAA-co-OEGMA) aqueous solution") when irradiated with ultraviolet light (wavelength: 365 nm) and visible light (wavelength > 400 nm). Figure 2 shows the results, i.e., the temperature dependence of the light transmittance of the P(AFBA-co-SPAA-co-OEGMA) aqueous solution. It can be seen from Figure 2 that the light transmittance of the P(AFBA-co-SPAA-co-OEGMA) aqueous solution when irradiated with ultraviolet light and visible light both decreased rapidly with increasing temperature. In addition, the decrease in light transmittance of the P(AFBA-co-SPAA-co-OEGMA) aqueous solution when irradiated with ultraviolet light occurred at around 42°C, whereas the decrease in light transmittance after irradiation with visible light occurred at a relatively low temperature of around 35°C. This is believed to be because the spiropyran group in P(AFBA-co-SPAA-co-OEGMA) isomerized from an open-ring to a closed-ring by visible light irradiation, increasing the hydrophobicity of P(AFBA-co-SPAA-co-OEGMA), and the LCST of the P(AFBA-co-SPAA-co-OEGMA) aqueous solution shifted from 42°C to 35°C. Therefore, it was confirmed that the LCST of the P(AFBA-co-SPAA-co-OEGMA) aqueous solution shifted to a lower temperature by visible light irradiation.
[0048] Figure 3 shows a photograph of an aqueous solution of P(AFBA-co-SPAA-co-OEGMA) irradiated with visible light of wavelengths over 400 nm for 10 seconds at 37°C. It can be seen from Figure 3 that the aqueous solution of P(AFBA-co-SPAA-co-OEGMA) became cloudy upon irradiation with visible light. This is believed to be because the spiropyran group in P(AFBA-co-SPAA-co-OEGMA) isomerized from an open-ring to a closed-ring, causing the LCST of the aqueous solution of P(AFBA-co-SPAA-co-OEGMA) to fall below 37°C. Therefore, it was confirmed that the water solubility of P(AFBA-co-SPAA-co-OEGMA) changed and precipitated when it was irradiated with visible light of wavelengths over 400 nm at 37°C.
[0049] (2) Uptake behavior of P(AFBA-co-SPAA-co-OEGMA) into normal and cancer cells As the evaluation cells, normal mouse fibroblast cells (L929 cells), cancer cells derived from human liver cancer (HepG2 cells) and human cervical cancer (Hela cells) were exposed to P(AFBA-co-SPAA-co-OEGMA) (1.0mg / ml) that had been irradiated with UV light (wavelength: 365nm) for 30 minutes in advance at 37℃ for 4 hours, and as a control, L929 cells, HepG2 cells and Hela cells that had not been exposed to P(AFBA-co-SPAA-co-OEGMA) were used to evaluate the uptake behavior into each cell. The evaluation was performed by measuring the fluorescence intensity of each cell using a flow cytometer (BECKMAN COULTER). The results are shown in Figure 4. As shown in Figure 4, the cancer cells HepG2 cells and Hela cells exposed to P(AFBA-co-SPAA-co-OEGMA) showed stronger fluorescence intensity than the respective controls. On the other hand, it was confirmed that when P(AFBA-co-SPAA-co-OEGMA) was contacted with L929 cells, which are normal cells, a peak was observed at the same position as the control. Furthermore, Figure 5 shows fluorescence microscopy images of normal L929 cells and cancer cells HepG2 and Hela cells contacted with P(AFBA-co-SPAA-co-OEGMA) that had been previously irradiated with ultraviolet light (wavelength: 365 nm) for 30 minutes at 37°C for 4 hours. As shown in Figure 5, only a slight amount of red fluorescence from P(AFBA-co-SPAA-co-OEGMA) was observed inside the cancer cells HepG2 and Hela cells. Therefore, it was confirmed that P(AFBA-co-SPAA-co-OEGMA) was taken up by both the cancer cells HepG2 and Hela cells, but was hardly taken up by the normal cells L929 cells. Thus, the reason why P(AFBA-co-SPAA-co-OEGMA) was effectively taken up by cancer cells is believed to be due to the high affinity between the diol in sialic acid overexpressed on the surface of cancer cells and the aromatic boronic acid in AFBA contained in P(AFBA-co-SPAA-co-OEGMA). The binding mode at this time is as shown in the chemical reaction formula below.
[0050] [ka]
[0051] (3) Cytotoxicity evaluation As in (2) above, the cytotoxicity of P(AFBA-co-SPAA-co-OEGMA) was evaluated under visible light irradiation and non-irradiation using HepG2 and Hela cells that had been exposed to P(AFBA-co-SPAA-co-OEGMA) for 4 hours at 37°C after being irradiated with UV light (wavelength: 365 nm) in advance. Figure 6 shows the cell viability (corresponding to "Vis irrad." in Figure 8) when cancer cells HepG2 and Hela cells were exposed to P(AFBA-co-SPAA-co-OEGMA) at various concentrations for 4 hours, washed, and then irradiated with visible light (wavelength: >400 nm) for 10 seconds. In addition, Figure 6 also shows the cell viability (corresponding to "Unirradiated" in Figure 6) of cancer cells HepG2 and Hela cells exposed to P(AFBA-co-SPAA-co-OEGMA) at various concentrations for 4 hours, washed, and not irradiated with visible light. Figure 6 shows that when not irradiated with visible light, both HepG2 and Hela cells showed high cell viability regardless of the P(AFBA-co-SPAA-co-OEGMA) concentration. This confirmed that P(AFBA-co-SPAA-co-OEGMA) has low cytotoxicity when not irradiated with visible light. On the other hand, when irradiated with visible light, the cell viability clearly decreased with increasing P(AFBA-co-SPAA-co-OEGMA) concentration in both HepG2 and Hela cells. This suggests that P(AFBA-co-SPAA-co-OEGMA) induces cell death only when irradiated with visible light.
[0052] (summary) From the above results, it was confirmed that the copolymer according to the present invention recognizes sialic acid overexpressed on the surface of cancer cells and is preferentially taken up by cancer cells. In addition, the LCST of the copolymer according to the present invention shifts to a lower temperature side of 37°C or less when irradiated with visible light in phosphate buffered saline at about 37°C. Therefore, the copolymer dissolved in phosphate buffered saline precipitates due to phase transition. For this reason, the copolymer can be precipitated in the cancer cells by irradiating the cancer cells that have taken up the copolymer according to the present invention with visible light using a catheter or the like, thereby inducing the death of the cancer cells. [Industrial Applicability]
[0053] The copolymer according to the present invention is expected to be applied in the medical field as a new cancer treatment method with reduced side effects.
Claims
1. a first monomer-derived component having a photoresponsive group that reversibly becomes hydrophobic or hydrophilic in response to light in a specific wavelength range; a second monomer-derived component having a functional group that selectively binds to a glycan expressed on the surface of a cancer cell; a third monomer-derived component having a temperature-responsive group that reversibly becomes hydrophobic or hydrophilic in response to temperature; Including, The lower critical solution temperature (LCST) shifts reversibly in response to light of a specific wavelength range. Copolymer.
2. the lower critical solution temperature (LCST) of the copolymer when irradiated with ultraviolet light is within a range of 40° C. or more and 100° C. or less; The copolymer according to claim 1, wherein the lower critical solution temperature (LCST) of the copolymer when irradiated with visible light is in the range of 0°C or more and 37°C or less.
3. A cancer therapeutic agent comprising the copolymer according to claim 1 or 2 as an active ingredient.
4. A method for producing a copolymer, comprising copolymerizing a first monomer having a photoresponsive group that reversibly becomes hydrophobic or hydrophilic in response to light in a specific wavelength range, a second monomer having a functional group that selectively binds to a glycan expressed on the surface of a cancer cell, and a third monomer having a temperature-responsive group that reversibly becomes hydrophobic or hydrophilic in response to temperature.
5. 5. The method for producing a copolymer according to claim 4, wherein the first monomer, the second monomer, and the third monomer are copolymerized so that the lower critical solution temperature (LCST) of the copolymer when irradiated with ultraviolet light is in the range of 40° C. or more and 100° C. or less, and the lower critical solution temperature (LCST) of the copolymer when irradiated with visible light is in the range of 0° C. or more and 37° C. or less.
